# FDA 483 - Maynard R. Rasmussen, M.D - May 06, 2022

Source: https://www.keypedia.com/records/483/maynard-r-rasmussen-md/88496dfd-f2e5-4d0b-8c70-8dc380f7402c

> FDA 483 for Maynard R. Rasmussen, M.D on May 06, 2022. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Maynard R. Rasmussen, M.D
- Inspection Date: 2022-05-06
- Product Type: drugs
- Office Name: Division of Pharmaceutical Quality Operations IV
- Summary: An FDA inspection of Maynard R. Rasmussen, M.D. in San Diego, CA, a clinical investigator, identified an issue with investigational drug disposition records. The firm failed to adequately document the dates and quantities for unused maintenance doses of study drug kits for multiple subjects. This indicates a deficiency in accountability for investigational products.

## Related Officers

- [Julian C. Hanson](https://www.keypedia.com/people/julian-c-hanson/489e27d9-0de6-4bf0-8aec-e5d500841f52)

Company: https://www.keypedia.com/companies/maynard-r-rasmussen-md/f33720b9-22ca-4391-8909-f4615b192d6a

Office: https://www.keypedia.com/offices/division-of-pharmaceutical-quality-operations-iv/a2d2ff91-dc0f-433e-b91f-ca90ff8998b6